CLGN
Price
$3.46
Change
-$0.11 (-3.08%)
Updated
Oct 2 closing price
Capitalization
7.32M
58 days until earnings call
Intraday BUY SELL Signals
SPRO
Price
$1.19
Change
-$0.07 (-5.56%)
Updated
Oct 2 closing price
Capitalization
69.3M
42 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

CLGN vs SPRO

CLGN vs SPRO Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
CLGN vs. SPRO commentary
Oct 05, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CLGN is a Hold and SPRO is a Hold.

Interact to see
Advertisement
SUMMARIES
Loading...
FUNDAMENTALS RATINGS
CLGN vs SPRO: Fundamental Ratings
CLGN
SPRO
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
98
Overvalued
58
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9948
PRICE GROWTH RATING
1..100
6685
P/E GROWTH RATING
1..100
288
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SPRO's Valuation (58) in the Pharmaceuticals Major industry is somewhat better than the same rating for CLGN (98) in the Biotechnology industry. This means that SPRO’s stock grew somewhat faster than CLGN’s over the last 12 months.

SPRO's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as CLGN (100) in the Biotechnology industry. This means that SPRO’s stock grew similarly to CLGN’s over the last 12 months.

SPRO's SMR Rating (48) in the Pharmaceuticals Major industry is somewhat better than the same rating for CLGN (99) in the Biotechnology industry. This means that SPRO’s stock grew somewhat faster than CLGN’s over the last 12 months.

CLGN's Price Growth Rating (66) in the Biotechnology industry is in the same range as SPRO (85) in the Pharmaceuticals Major industry. This means that CLGN’s stock grew similarly to SPRO’s over the last 12 months.

CLGN's P/E Growth Rating (2) in the Biotechnology industry is significantly better than the same rating for SPRO (88) in the Pharmaceuticals Major industry. This means that CLGN’s stock grew significantly faster than SPRO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CLGNSPRO
RSI
ODDS (%)
Bearish Trend 3 days ago
86%
Bearish Trend 3 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
81%
Bullish Trend 3 days ago
83%
Momentum
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
69%
MACD
ODDS (%)
Bearish Trend 3 days ago
88%
N/A
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
87%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
89%
Bearish Trend 3 days ago
88%
Advances
ODDS (%)
Bullish Trend 10 days ago
82%
Bullish Trend 4 days ago
72%
Declines
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 7 days ago
89%
BollingerBands
ODDS (%)
Bearish Trend 5 days ago
90%
Bearish Trend 3 days ago
83%
Aroon
ODDS (%)
Bullish Trend 3 days ago
86%
Bearish Trend 3 days ago
87%
COMPARISON
Comparison
Oct 05, 2026
Stock price -- (CLGN: $3.46 vs. SPRO: $1.19)
Brand notoriety: CLGN and SPRO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CLGN: 9% vs. SPRO: 122%
Market capitalization -- CLGN: $7.32M vs. SPRO: $69.3M
CLGN [@Biotechnology] is valued at $7.32M. SPRO’s [@Biotechnology] market capitalization is $69.3M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $133.74B. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CLGN’s FA Score shows that 1 FA rating(s) are green while SPRO’s FA Score has 0 green FA rating(s).

  • CLGN’s FA Score: 1 green, 4 red.
  • SPRO’s FA Score: 0 green, 5 red.
According to our system of comparison, both CLGN and SPRO are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CLGN’s TA Score shows that 3 TA indicator(s) are bullish while SPRO’s TA Score has 4 bullish TA indicator(s).

  • CLGN’s TA Score: 3 bullish, 7 bearish.
  • SPRO’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, SPRO is a better buy in the short-term than CLGN.

Price Growth

CLGN (@Biotechnology) experienced а -18.59% price change this week, while SPRO (@Biotechnology) price change was -3.25% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.69%. For the same industry, the average monthly price growth was -14.41%, and the average quarterly price growth was -1.73%.

Reported Earning Dates

CLGN is expected to report earnings on Dec 02, 2026.

SPRO is expected to report earnings on Nov 16, 2026.

Industries' Descriptions

@Biotechnology (-3.69% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
CLGN
Daily Signal:
Gain/Loss:
SPRO
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
IHF55.090.72
+1.32%
iShares U.S. Healthcare Providers ETF (IHF)
NBH9.150.08
+0.88%
Neuberger Municipal Fund Inc.
BYRE25.480.09
+0.35%
Principal Real Estate Active Opportunities ETF (BYRE)
XPEG4.96N/A
N/A
Leverage Shares 2X Long Xpev Daily ETF
LDRC24.55-0.12
-0.49%
iShares iBonds 1-5 Year Corporate Ladder ETF

CLGN and

Correlation & Price change

A.I.dvisor tells us that CLGN and CLLS have been poorly correlated (+33% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CLGN and CLLS's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CLGN
1D Price
Change %
CLGN100%
-3.08%
CLLS - CLGN
33%
Poorly correlated
+2.14%
SPRO - CLGN
30%
Poorly correlated
-5.56%
ACET - CLGN
26%
Poorly correlated
-2.11%
ALZN - CLGN
26%
Poorly correlated
+3.01%
VOR - CLGN
25%
Poorly correlated
+3.49%
More

SPRO and

Correlation & Price change

A.I.dvisor indicates that over the last year, SPRO has been loosely correlated with CCXI. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if SPRO jumps, then CCXI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SPRO
1D Price
Change %
SPRO100%
-5.56%
CCXI - SPRO
48%
Loosely correlated
+3.18%
ASBP - SPRO
42%
Loosely correlated
+8.25%
RXRX - SPRO
35%
Loosely correlated
+1.23%
JAGX - SPRO
34%
Loosely correlated
-7.34%
VYGR - SPRO
33%
Loosely correlated
-8.41%
More